Stockscreener 앱 받기
105.87
0.10%
0.11
전일 마감가:
$105.76
열려 있는:
$106.38
하루 거래량:
631.80K
Relative Volume:
0.55
시가총액:
$26.57B
수익:
$3.53B
순이익/손실:
$-632.54M
주가수익비율:
-40.26
EPS:
-2.6296
순현금흐름:
$-588.89M
1주 성능:
-0.70%
1개월 성능:
-1.23%
6개월 성능:
-6.13%
1년 성능:
-13.77%
1일 변동 폭
$105.70
$108.00
1주일 범위
$105.58
$112.68
52주 변동 폭
$81.20
$124.49
바이오앤테크 Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
105.87 | 26.54B | 3.53B | -632.54M | -588.89M | -2.6296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider - GlobeNewswire Inc.
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data - The Globe and Mail
BioNTech (NASDAQ:BNTX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? - Finviz
Leerink downgrades BioNTech to “market perform” after 24% share rally - Investing.com
Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer - TipRanks
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? - Finviz
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline - Finviz
BioNTech's Strategic Pivot Gains Momentum with Key Oncology Milestones () - aktiencheck.de
BioNTech SE (BNTX): A Bull Case Theory - Finviz
2 Biotech Stocks Set to Rebound in 2026 - Finviz
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX - TipRanks
BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial - TipRanks
BioNTech Shares Gain Momentum on Regulatory and Analyst Support () - aktiencheck.de
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts - Meyka
BioNTech (BNTX) soars 11.8%: Is further upside left in the stock? - MSN
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Nasdaq
BioNTech (NASDAQ:BNTX) Trading 7.5% HigherHere's Why - MarketBeat
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors - TipRanks
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - yourwyominglink.com
What to Expect From Pfizer's Non-Oncology Business in Q4? - The Globe and Mail
BioNTech's Strategic Pivot: A Deep Dive into Its Expanding Oncology Pipeline () - aktiencheck.de
Goldman Sachs upgrades BioNTech stock to Buy on oncology potential - Investing.com
SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It - Chartmill
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan - Yahoo Finance
BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial - TipRanks
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - Finviz
BioNTech Finalizes CureVac Acquisition, Shifts Focus to Integration () - aktiencheck.de
BioNTech: CN Considers to Approve Use of BioNTech Vaccine for Foreigners in CN - AASTOCKS.com
Scientists Question Pfizer, BioNTech's Vaccine Effectiveness - AASTOCKS.com
BioNTech, Pfizer See Covid Vaccine Capacity Rise to 3B Doses Next Yr - AASTOCKS.com
CureVac shares to be delisted from Nasdaq following BioNTech acquisition By Investing.com - Investing.com South Africa
FOSUN PHARMA Pairs with BioNTech to Supply BioNTech Vaccine to Germans in CN - AASTOCKS.com
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
1.12%
자본화:
|
볼륨(24시간):